Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 8 of 8 results for tezacaftor with ivacaftor

  1. Data collection agreement

    treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with...

  2. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued [GID-TA10277]

    Technology appraisal guidance
    Discontinued

  3. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued [GID-TA10566]

    Technology appraisal guidance
    Discontinued

  4. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

    Technology appraisal guidance
    Published
    24 July 2024
    View recommendations

    Sections for TA988

  5. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]

    In development [GID-TA11430] Expected publication date: 21 August 2025

    Technology appraisal guidance
    In development

  7. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

    NICE guideline
    Published
    25 October 2017
    View recommendations

    Sections for NG78

  8. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]

    Awaiting development [GID-TA11372] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development